medigraphic.com
Instituto Nacional de Salud Pública

2008, Number 5

<< Back Next >>

salud publica mex 2008; 50 (5)

Prevalence of neutralizing antibodies to dengue virus serotypes in university students from Tabasco, Mexico.

Sánchez-Burgos GG, López-Alvarado MA, Castañeda-Desales D, Ruiz-Gómez J, Ramos-Castañeda J

Language: Spanish
References: 12
Page: 362-366
PDF size: 154.44 Kb.


ABSTRACT

Objective. Determine the seroprevalence of neutralizing antibodies to dengue virus in students from the state university of Tabasco, Mexico. Material and Methods. A transversal study was conducted of serum collected from students between September and November, 2005. The sera were screened for anti-dengue IgG and those that had evidence of dengue antibodies were analyzed by a plaque reduction neutralization test. Results. Prevalence of anti-dengue IgG was 9.1%. The frequency of neutralizing antibodies was 100% for DENV-2, 68% for DENV-4, 20% for DENV-1, and 4 % for DENV-3. Conclusions. We found that in this population, DENV-2 circulates more than DENV-3 despite the fact that DENV-3 is more frequently isolated. Unexpectedly, neutralizing antibodies against DENV-4 were frequently found even though this serotype is almost extinct; thus, it is probable that cross-immunity could suppress DEN-4 transmission, as has been suggested.


REFERENCES

  1. Kroeger A, Nathan M, Hombach J. Dengue. Nat Rev Microbiol 2004;2(5):360-361.

  2. Ligon BL. Dengue fever and dengue hemorrhagic fever: a review of the history, transmission, treatment, and prevention. Semin Pediatr Infect Dis 2005;16(1):60-65.

  3. Anderson KB. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 2007;369(9571):1452-1459.

  4. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006;19(5):429-436.

  5. Wearing HJ, Rohani P. Ecological and immunological determinants of dengue epidemics. Proc Natl Acad Sci USA 2006;103(31):11802-11807.

  6. Halstead SB. Dengue in the Americas and Southeast Asia: do they differ? Rev Panam Salud Publica 2006;20(6):407-415.

  7. Navarrete-Espinosa J.Prevalence of dengue and leptospira antibodies in the state of Veracruz, Mexico. Salud Publica Mex 2006;48(3):220-228.

  8. Lorono-Pino MA, Farfan-Ale JA, Rosado-Paredes EP, Arjona-Torres AI,Flores-Flores LF, Manzano-Cabrera LA, et al. Prevalencia de anticuerpos contra el virus dengue en Yucatán, México, 1985. Rev Latinoam Microbiol 1989;31:259-262.

  9. SINAVE. Dirección General de Epidemiología. Secretaría de Salud.[Consultado en septiembre de 2007]. Disponible en: http://www.dgepi. salud.gob.mx/sinave/index.htm.

  10. Guzman MG. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 2007; 13(2):282-186.

  11. Adams B. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci USA 2006;103(38):14234-14239.

  12. Guzman MG. Epidemiologic studies on Dengue in Santiago de Cuba,1997. Am J Epidemiol 2000;152(9):793-799; discussion 804.




2020     |     www.medigraphic.com